Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth
Executive Summary
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.
You may also be interested in...
Teva’s Cubicin Authorized Generic Is First Rival To Merck’s Brand
Teva launched an authorized generic version of Merck’s blockbuster antibiotic, while Pfizer did not provide an update on the timeline of a generic launch for which a court decision paved the way.
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.
Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)
Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.